sd3445,
As DNAPrint has stated previously, that is due to the financing pinch, and I think it should come as no surprise.
If/when the funding problem is resolved, it is reasonable to assume the financial reports, etc., will resume normally. It is positive that the company already had income streams, and has obviously drastically cut expenses -- necessary steps to survive in such a financing pinch.
What we've recently learned about the company (from Sarah, and PL1,) is encouraging, in my opinion; the reports of the death of the lab are greatly exaggerated. I'm particularly encouraged by Sarah's statement, that the lab instrument that is down, should be back up and running within a few weeks. What PL1 reports about the lab, and the staffing, is also encouraging. Some people may wish to see the lab fully staffed at this time, but in a financing pinch, that can be suicidal for a company. Cutting costs, in my opinion, is a very responsible thing for the company to have done. I trust they are making sound decisions, in controlling costs while trying to maximize revenues. I may be mistaken, but it's an educated guess, and a gesture consistent with the good faith that I've seen the company consistently act on.
Anyway, my convictions about this company and its stock do not require any particular person(s) to agree with me. I've simply been putting my money where my convictions are, following my established investment strategies. I'm essentially an extreme value investor; I like to buy when practically everyone else is too afraid to buy. This strategy has been paying off well, for me. Of course there is risk, and I do not wish anyone to be unaware of that.
Daniel
